Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-04-17
2004-11-30
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S482000, C514S484000, C514S488000, C514S485000
Reexamination Certificate
active
06825224
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
The present invention relates to novel compounds, methods of preparing these compounds, and pharmaceutical compositions comprising these compounds. These compounds are carbamate prodrugs that convert to active inhibitors of the IMPDH enzyme in vivo. The compounds and pharmaceutical compositions of this invention are particularly well suited for activation and subsequent inhibition of the IMPDH enzyme activity. Consequently, these prodrugs may be advantageously used as therapeutic agents for IMPDH mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds and compositions of this invention.
BACKGROUND OF THE INVENTION
IMPDH (EC 1.1.1.205) is an enzyme involved in the de novo synthesis of guanosine nucleotides. The synthesis of nucleotides in organisms, in general, is required for the cells in those organisms to divide and replicate. Nucleotide synthesis in mammals may be achieved through one of two pathways: the de novo synthesis pathway or the salvage pathway. Different cell types use these pathways to different extents. IMPDH catalyzes the NAD-dependent oxidation of inosine-5′-monophosphate (IMP) to xanthosine-5′-monophosphate (XMP)[Jackson R. C. et. al.,
Nature
, 256, pp. 331-333, (1975)].
IMPDH is ubiquitous in eukaryotes, bacteria and protozoa [Y. Natsumeda & S. F. Carr,
Ann. N.Y. Acad
., 696, pp. 88-93 (1993)]. The prokaryotic forms share 30-40% sequence identity with the human enzyme. Two isoforms of human IMPDH, designated type I and type II, have been identified and sequenced [F. R. Collart and E. Huberman,
J. Biol. Chem
., 263, pp. 15769-15772, (1988); Y. Natsumeda et. al.,
J. Biol. Chem
., 265, pp. 5292-5295, (1990)]. Each is 514 amino acids, and they share 84% sequence identity.
The de novo synthesis of guanosine nucleotides, and thus the activity of IMPDH, is particularly important in B and T-lymphocytes. These cells depend on the de novo, rather than salvage pathway to generate sufficient levels of nucleotides necessary to initiate a proliferative response to mitogen or antigen [A. C. Allison et. al.,
Lancet
2(7946), pp. 1179-1183, (1975) and A. C. Allison et. al.,
Ciba Found. Symp
., 48, pp. 207-224, (1977)]. Thus, IMPDH is an attractive target for selectively inhibiting the immune system without also inhibiting the proliferation of other cells.
In addition to its role in the immune response, it is also known that IMPDH plays a role in other metabolic events. Increased IMPDH activity has been observed in rapidly proliferating human leukemic cell lines and other tumor cell lines, indicating IMPDH as a target for anti-cancer as well as immunosuppressive chemotherapy [M. Nagai et. al.,
Cancer Res
., 51, pp. 3886-3890, (1991)]. IMPDH has also been shown to play a role in the proliferation of smooth muscle cells, indicating that inhibitors of IMPDH, such as MPA or rapamycin, may be useful in preventing restenosis or other hyperproliferative vascular diseases [C. R. Gregory et al.,
Transplantation
, 59, pp. 655-61 (1995); PCT publication WO 94/12184; and PCT publication WO 94/01105].
Additionally, IMPDH has been shown to play a role in viral replication in some viral cell lines. [S. F. Carr,
J. Biol. Chem
., 268, pp. 27286-27290 (1993)]. Analogous to lymphocyte and tumor cell lines, the implication is that the de novo, rather than the salvage, pathway is critical in the process of viral replication.
Mycophenolic acid (MPA) and some of its derivatives have been described as inhibitors of IMPDH [U.S. Pat. Nos. 5,380,879 and 5,444,072 and PCT publications WO 94/01105 and WO 94/12184]. These compounds are potent, non-competitive, reversible inhibitors of human IMPDH type I (K
i
=33 nM) and type II (K
i
=9 nM). MPA has been demonstrated to block the response of B and T-cells to mitogen or antigen [A. C. Allison et. al.,
Ann. N. Y. Acad. Sci
., 696, pp. 63-87, (1993)]. MPA is characterized by undesirable pharmacological properties, however, such as gastrointestinal toxicity and poor bioavailability. [L. M. Shaw, et. al.,
Therapeutic Drug Monitoring
, 17, pp. 690-699, (1995)].
Mycophenolate mofetil (MMF), a prodrug which quickly liberates free MPA in vivo, has been approved to prevent acute renal allograft rejection following kidney transplantation. [L. M. Shaw, et. al.,
Therapeutic Drug Monitoring
, 17, pp. 690-699, (1995); H. W. Sollinger,
Transplantation
, 60, pp. 225-232 (1995)]. Several clinical observations, however, limit the therapeutic potential of this drug. [L. M. Shaw, et. al.,
Therapeutic Drug Monitoring
, 17, pp. 690-699, (1995)]. First, the active drug, MPA, is rapidly metabolized to the inactive glucuronide in vivo. [A. C., Allison and E. M. Eugui,
Immunological Reviews
, 136, pp. 5-28 (1993)]. The glucuronide then undergoes enterohepatic recycling causing accumulation of MPA in the gastrointestinal tract where it cannot exert its IMPDH inhibitory activity on the immune system. This effectively lowers the drug's in vivo potency, while increasing its undesirable gastrointestinal side effects. In addition, MMF has inherent drawbacks as a prodrug. MMF is the morpholinoethyl ester of MPA. In vivo MMF is deesterified to MPA, but this hydrolysis can occur over a wide pH range in an aqueous environment. Therefore, it is difficult to control the time and location of activation of the drug.
Urea derivatives, which are more effective than MPA as inhibitors of IMPDH, have recently been described in U.S. Pat. No. 5,807,876 and in co-pending continuation applications 08/801,780 and 08/832,165, herein incorporated by reference. These compounds exhibit both an increased overall therapeutic effect and decreased deleterious side effects in their inhibition of IMPDH and in their use as compositions. But the aqueous solubility of these compounds is less than optimum.
The aqueous solubility of an organic molecule can impact its absorption following oral administration. For example, the oral administration of a highly hydrophobic compound can very easily result in poor absorption due to precipitation in the gastrointestinal tract. Formulation of such hydrophobic compounds with surfactants and complexing agents can improve the aqueous solubility of these compounds, but this method becomes more impractical as the aqueous solubility decreases. However, chemical modification of a drug into a bio- or chemically-reversible prodrug can confer temporary aqueous solubility to the drug substance that allows absorption following oral administration.
For orally administered prodrugs, the drug substance's kinetic solubility in neutral to acidic media is of most interest. In most cases, the kinetic solubility in these media is higher than the corresponding thermodynamic solubility. Therefore, it is advantageous to utilize this transient increase in solubility that immediately follows the conversion of the prodrug to the drug substance. The time it takes to reach thermodynamic equilibrium will vary from compound to compound and can only be determined experimentally. A strategy for creating prodrugs of IMPDH inhibitors that exploits the compound's kinetic solubility would be advantageous. Alternatively, a prodrug which liberates the drug substance as a fine dispersion intestinally may also improve its oral absorption, with smaller particle sizes being preferred.
Prodrug strategies which rely on intramolecular cyclization/transacylation to liberate a drug substance and a lactam derivative have been described where the liberated drugs are alcohols, phenols, and primary and secondary amines. For alcohols [Saari, et al,
J. Med. Chem
., 33, pp. 2590-2595 (1990)] and phenols [Saari, et al,
J. Med. Chem
., 33, pp. 97-101 (1990)], the facility of cyclization and hydroxyl liberation is a consequence of the lower pK
a
of the resulting leaving group (pK
a
10-16). Such prodrugs are easily prepared by known metho
Bethiel Randy S.
Stamos Dean P.
Cook Rebecca
Fish & Neave LLP
Haley Jr. James F.
Morris Greg A.
Vertex Pharmaceuticals Incorporated
LandOfFree
Prodrugs of carbamate inhibitors of IMPDH does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prodrugs of carbamate inhibitors of IMPDH, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs of carbamate inhibitors of IMPDH will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3359753